| Literature DB >> 35368498 |
Ramanarayana Boyapati1, Hema Duddukuri2, Ravindranath Dhulipalla1, Lakshmikanth Kolaparthy1, Tejaswin Polepalle1, Kishore Kumar Katuri1.
Abstract
Background: With the reports of oral manifestations observed in coronavirus disease 2019 (COVID-19) patients snowballing day-by-day, it calls for the attention of dental professionals to keep themselves updated regarding these manifestations and how to prevent and manage them in COVID-infected patients. Aims andEntities:
Keywords: Coronavirus disease 2019; coronavirus disease tongue; dental professionals; oral manifestations
Year: 2022 PMID: 35368498 PMCID: PMC8971885 DOI: 10.4103/ijcm.ijcm_704_21
Source DB: PubMed Journal: Indian J Community Med ISSN: 0970-0218
Correlation of participants background characteristics with their experience of providing oral health care for and noticing oral manifestations among coronavirus disease 2019 infected/treated participants (n=623)
| Variable | Category ( | Question 1 | Question 2 | ||
|---|---|---|---|---|---|
|
|
| ||||
| Yes, |
| Yes, |
| ||
| Gender | Male (281) | 190 (67.6) | <0.001* | 67 (23.8) | <0.001* |
| Female (342) | 97 (28.4) | 41 (12) | |||
| Specialty | None (BDS) (228) | 51 (22.9) | <0.001* | 32 (13.7) | <0.001* |
| Oral surgery (47) | 42 (89.3) | 19 (40.4) | |||
| Endodontics (61) | 41 (67.2) | 11 (18) | |||
| Orthodontics (33) | 26 (78.8) | 11 (33.3) | |||
| Prosthodontics (37) | 26 (70.3) | 10 (27) | |||
| Periodontics (113) | 49 (43.4) | 15 (13.3) | |||
| Pedodontics (49) | 19 (38.8) | 5 (10.2) | |||
| Public health dentistry (30) | 14 (46.7) | 2 (6.7) | |||
| Oral medicine and radiology (16) | 12 (75) | 1 (6.2) | |||
| Oral pathology (9) | 7 (77.8) | 2 (22.2) | |||
| Clinical experience (years) | <5 (346) | 96 (27.7) | <0.001* | 49 (14.2) | <0.001* |
| 5-10 (86) | 42 (48.8) | 10 (11.6) | |||
| 11-15 (75) | 55 (73.3) | 28 (37.3) | |||
| >15 (116) | 94 (81) | 21 (18.1) | |||
| Location of workplace | Metropolitan (159) | 93 (58.5) | 0.092 | 21 (13.2) | 0.001* |
| Rural (322) | 132 (41) | 66 (20.5) | |||
| Urban (142) | 62 (43.7) | 21 (14.8) | |||
Chi-square test; P≤0.05 considered statistically significant; *Statistical significance. Question 1: Have you had the experience of treating or screening participants who are diagnosed/treated for COVID-19?, Question 2: Have you seen participants who are diagnosed/treated for COVID-19 presenting with oral manifestations?, COVID-19: Coronavirus disease 2019
Oral manifestations observed and the respective treatments provided to the coronavirus disease 2019 diagnosed/recovered patients as reported by the study participants
| Oral manifestations in COVID-19 diagnosed/recovered patients | Treatments provided |
|---|---|
| Osteomyelitis ( | Surgical debridement; resection; medication |
| Ulcerations ( | Multivitamin supplements; topical analgesic gels |
| Candidiasis ( | Antifungals |
| Tooth mobility ( | Scaling and root planing followed by splinting; extraction |
| Gingival bleeding ( | Prescribed chlorhexidine mouthwash. Oral hygiene instructions given. Scaling and root planing performed after patient tested COVID negative |
| Mucormycosis ( | Resection and obturator placement |
| Severe bone loss ( | Flap surgery |
| Multiple abscesses/sinus openings ( | Antibiotics |
| Bruxism ( | Night guard |
| Xerostomia ( | Not specified |
| Gingival enlargement (3) | Not specified |
| Loss of taste and smell ( | Not specified |
| Others* (5) | Not specified |
*Aphthous stomatitis with burning sensation, tonsillitis and redness of tongue, halitosis, periodontitis, dry socket (1 each). n: Number of cases reported for each oral manifestation noticed by the participants, COVID-19: Coronavirus disease 2019
Participants’ knowledge toward coronavirus disease 2019-related oral manifestations (n=623)
| Knowledge associated questions concerning COVID-19-related oral manifestations: | |
|---|---|
| COVID-19 patients who are most susceptible to develop oral manifestations: | |
| Asymptomatic patients | 92 (14.8) |
| Long haulers (✓) | 213 (34.2) |
| COVID-19 infected patients with underlying systemic diseases (✓) | 497 (79.8) |
| Patients with severe COVID-19 infection requiring hospitalization (✓) | 307 (49.3) |
| Oral manifestations that can be seen in covid-19 patients: (all the options were correct responses) | |
| Opportunistic infections | 364 (58.4) |
| Ulcerations and blisters | 371 (59.6) |
| Desquamative gingivitis | 103 (16.5) |
| Fixed drug eruptions | 50 (8) |
| Xerostomia | 191 (30.7) |
| Gingivitis | 160 (25.7) |
| Melanin hyperpigmentation | 30 (4.8) |
| Altered/loss of taste | 411 (66) |
| Recurrent oral HSV infections | 80 (12.8) |
| Petechiae | 51 (8.2) |
| Tooth loss | 64 (10.3) |
| Necrotizing disease | 158 (25.4) |
| Burning sensation | 168 (27) |
| Tongue depapillation | 211 (33.9) |
| Osteomyelitis | 216 (34.7) |
| Occurrence of COVID-19-related oral manifestations is: (all the options were correct responses) | |
| Due to COVID-19 infection | 272 (43.7) |
| Secondary to the deterioration of systemic health | 478 (76.7) |
| Due to treatments for COVID-19 | 356 (57.1) |
| Predisposing factors for COVID-19-related oral manifestations: (all the options were correct responses) | |
| Poor oral hygiene | 381 (61.2) |
| Trauma secondary to intubation | 100 (16.1) |
| Underlying systemic diseases | 432 (69.3) |
| Stress | 315 (50.6) |
| Old age | 275 (44.1) |
| Hyperinflammatory response secondary to COVID-19 infection | 360 (57.8) |
| Drugs used for treatment of COVID-19 which are more likely to cause COVID-19-related oral manifestations when used for longer duration: | |
| Anti-viral (✓) | 326 (52.3) |
| Anticoagulants | 50 (8) |
| Steroids (✓) | 500 (80.3) |
| Antimalarial | 52 (8.3) |
| Supplements | 58 (9.3) |
COVID-19: Coronavirus disease 2019, HSV: Herpes simplex virus
Mean knowledge scores and differences based on the background characteristics of the participants (n=623)
| Variable | Category | Mean±SD |
|
|---|---|---|---|
| Gender | Male | 13.55±4.97 | 0.001a* |
| Female | 10.49±4.27 | ||
| Specialty | None (BDS) | 10.5±4.39 | <0.001* |
| Oral surgery | 14.19±5.09 | ||
| Endodontics | 12.7±4.84 | ||
| Orthodontics | 15.03±3.19 | ||
| Prosthodontics | 13.59±4.27 | ||
| Periodontics | 11.15±5.34 | ||
| Pedodontics | 11.67±3.87 | ||
| Public health dentistry | 12.27±5.14 | ||
| Oral medicine and radiology | 15.63±4.71 | ||
| Oral pathology | 12±4.61 | ||
| Years of clinical experience | <5 | 10.67±4.35 | <0.001* |
| 5-10 | 10.24±4.22 | ||
| 11-15 | 13.71±4.43 | ||
| >15 | 15.48±4.74 | ||
| Location of workplace | Metropolitan | 13.77±5.03 | <0.001* |
| Urban | 11.18±4.72 | ||
| Rural | 11.31±4.36 |
Kruskal-Wallis ANOVA; aMann-Whitney U-test; P≤0.05 considered statistically significant; *Statistical significance. SD: Standard deviation
Multiple linear regression model showing characteristics significantly related to knowledge scores regarding coronavirus disease 2019-related oral manifestations (n=623)
| Characteristic | β | SE |
|
|
|---|---|---|---|---|
| Gender (Reference:Female) | ||||
| Gender (male) | 0.887 | 0.465 | 1.908 | 0.057 |
| Specialty (Reference:BDS) | ||||
| Oral and maxillofacial surgery | 1.595 | 0.758 | 2.105 | 0.036* |
| Endodontics | −0.06 | 0.7 | −0.094 | 0.925 |
| Orthodontics | 1.014 | 0.939 | 1.081 | 0.28 |
| Prosthodontics | 1.273 | 0.827 | 1.541 | 0.124 |
| Periodontics | 0.09 | 0.561 | 0.161 | 0.872 |
| Pedodontics | −0.311 | 0.745 | −0.417 | 0.676 |
| Public health dentistry | 0.167 | 0.89 | 0.188 | 0.851 |
| Oral medicine and radiology | 3.193 | 1.202 | 2.656 | 0.008* |
| Oral pathology | 0.813 | 1.537 | 0.529 | 0.597 |
| Clinical experience (Reference: <5 years) | ||||
| 5-10 | −1.11 | 0.601 | −1.862 | 0.063 |
| 11-15 | 1.99 | 0.69 | 2.886 | 0.004* |
| >15 | 3.034 | 0.652 | 4.653 | 0.001* |
| Location (Reference: Metropolitan) | ||||
| Urban | −1.341 | 0.461 | −2.91 | 0.004* |
| Rural | −1.697 | 0.531 | −3.19 | 0.001* |
| Intercept | 10.675 | 0.724 | 14.734 | 0.001* |
R=0.429; R2=0.184; Adjusted R2=0.166; P≤0.05 considered statistically significant; *Statistical significance. SE: Standard error